Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease

Elena M. Yubero-Serrano, Mark Woodward, Leonid Poretsky, Helen Vlassara, Gary E. Striker, Study Group Age-Less Study Group, Leonid Poretsky, Gary E. Striker, Agustin Busta, Nikolas B. Harbord, Kobena Dadzie, Julie Islam, Usman Ali, Ronald Tamler, Grishma Parikh, Eliot Rayfield, Luba Rakhlin, Jaime Uribarri, Rebecca Kent, Kamala Mantha-ThalerLynn Polmanteer, Megan Fendt, Anita Kalaj, Elizabeth McKee, Elizabeth Tripp, Renata A. Pyzik, Lauren Tirri, Johanna F. Kruckelmann, Shobha M. Swamy, Xue Chen, Weijing Cai, Sharon J. Elliot

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


Background and objectives The primary goals were to re-examine whether sevelamer carbonate (SC) reduces advanced glycation end products (AGEs) (methylglyoxal and carboxymethyllysine [CML]), increases antioxidant defenses, reduces pro-oxidants, and improves hemoglobin A1c (HbA1c) in patients with type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD). Secondary goals examined albuminuria, age, race, sex, and metformin prescription. Design, setting, participants, & measurements This two-center, randomized, intention-to-treat, open-label study evaluated 117 patients with T2DM(HbA1c.6.5%) and stages 2–4 DKD (urinary albumin/creatinine ratio $200 mg/g) treated with SC (1600 mg) or calcium carbonate (1200 mg), three times a day, without changing medications or diet. Statistical analyses used linear mixed models adjusted for randomization levels. Preselected subgroup analyses of sex, race, age, and metformin were conducted. Results SC lowered serum methylglyoxal (95% confidence interval [CI], 20.72 to 20.29; P,0.001), serum CML (95% CI, 25.08 to 21.35; P≤0.001), and intracellular CML (95% CI, 21.63 to 20.28; P=0.01). SC increased anti-inflammatory defenses, including nuclear factor like-2 (95% CI, 0.58 to 1.29; P=0.001), AGE receptor 1 (95% CI, 0.23 to 0.96; P=0.001), NAD-dependent deacetylase sirtuin-1 (95% CI, 0.20 to 0.86; P=0.002), and estrogen receptor a (95% CI, 1.38 to 2.73; P ≤0.001). SC also decreased proinflammatory factors such as TNF receptor 1 (95% CI, 21.56 to 20.72; P≤0.001) and the receptor for AGEs (95% CI, 20.58 to 1.53; P≤0.001). There were no differences in HbA1c, GFR, or albuminuria in the overall group. Subanalyses showed that SC lowered HbA1c in women (95% CI, 21.71 to 20.27; P=0.01, interaction P=0.002), and reduced albuminuria in those aged,65 years (95% CI, 21.15 to 20.07; P=0.03, interaction P=0.02) and non-Caucasians (95% CI, 21.11 to 20.22; P=0.003, interaction P≤0.001), whereas albuminuria increased after SC and calcium carbonate in Caucasians. Conclusions SC reduced circulating and cellular AGEs, increased antioxidants, and decreased pro-oxidants, but did not change HbA1c or the albumin/creatinine ratio overall in patients with T2DM and DKD. Because subanalyses revealed that SC may reduce HbA1c and albuminuria in some patients with T2DM with DKD, further studies may be warranted.

Original languageEnglish
Pages (from-to)759-766
Number of pages8
JournalClinical Journal of the American Society of Nephrology
Issue number5
StatePublished - 1 Jan 2015


Dive into the research topics of 'Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease'. Together they form a unique fingerprint.

Cite this